Jaguar Gene Therapy Bolsters Leadership Team with Appointment of Joseph W. McIntosh, MD, as Chief Medical Officer

EFFECTIVE DATE:

Chartwell Partners is pleased to announce the recruitment of Joe McIntosh, MD, as Chief Medical Officer for Jaguar Gene Therapy. Backed by Deerfield Management, ARCH Venture Partners, Goldman Sachs, Nolan Capital, and Eli Lilly, and based in Lake Forest, IL, Jaguar Gene Therapy is led by former AveXis leadershipleveraging a proven management team with the expertise to accelerate the development, manufacturing, and commercialization of novel gene therapy treatments. Joe McIntosh, MD, joins from Aruvant where he served as Chief Medical Officer, overseeing clinical development, regulatory, pharmacovigilance and medical affairs and leading the development of the company’s investigational gene therapy for sickle cell disease. Prior to that, he served as Senior Vice President, Head of Clinical Development, at PTC Therapeutics, where he managed a portfolio of clinical studies across the therapeutic areas of genetic diseases and oncology. Dr. McIntosh held earlier positions at NPS Pharmaceuticals, Eisai, and Pfizer.

 

For more information on this appointment, please visit: https://jaguargenetherapy.com/news/appoints-joseph-mcintosh-chief-medical-officer